Literature DB >> 8598950

Loop electrosurgical excision procedure for squamous intraepithelial lesions of the cervix: advantages and potential pitfalls.

A Ferenczy1, D Choukroun, J Arseneau.   

Abstract

OBJECTIVE: to evaluate the advantages and pitfalls of the loop electrosurgical excision procedure as applied to the diagnosis and treatment of cervical cancer precursors.
METHODS: Loop electrosurgical excision procedure using local anesthesia and colposcopic guidance was performed in an outpatient clinical setting in 1189 consecutive patients referred for colposcopy for an abnormal Papanicolaou smear during a period of 4 years.
RESULTS: Of the 1189 patients, 915 (77%) were managed in one sitting with the "see and treat" approach, and in 274 patients endocervical curettage and cervical biopsies preceded loop electrosurgical excision procedure. One hundred nineteen (10%) patients were lost to follow-up. Twenty-one patients had either adenocarcinoma in situ (15) or microinvasive squamous cell carcinoma (six) in the loop electrosurgical excision procedure specimen, whereas the electroexcised specimens contained no lesional tissue in 166 (14%) patients. Cure (ie, disease-free at 6 months or longer) was observed in 92% of the 883 evaluable patients after a single treatment and 95% after a repeat loop electrosurgical excision procedure. High-grade squamous intraepithelial lesion was successfully treated with loop electrosurgical excision procedure in 287 (93%) of 309 patients. Complications, mainly intra- and postoperative bleeding, occurred in 7% of the patients. In most loop electrosurgical excision procedure-negative cases, the referral cytologic diagnosis or colposcopy and/or history were false-positive on review, or the biopsies performed before loop electrosurgical excision procedure removed smaller areas of abnormal tissue.
CONCLUSION: Loop electrosurgical excision procedure using the see and treat approach should be limited to cytologically and colposcopically unequivocal intraepithelial lesions, and depth of excision should be controlled by colposcopy using loop electrodes of appropriate size. In doubtful cases, particularly in the young patient, disease should be ascertained by expert histology and colposcopy before definite therapy. Loop electroexcision represents an attractive means of diagnosing and treating cervical cancer precursors.

Entities:  

Mesh:

Year:  1996        PMID: 8598950     DOI: 10.1016/0029-7844(95)00453-x

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  9 in total

1.  Completeness of excision and follow up cytology in patients treated with loop excision biopsy.

Authors:  A M Zaitoun; G McKee; M J Coppen; S M Thomas; P O Wilson
Journal:  J Clin Pathol       Date:  2000-03       Impact factor: 3.411

2.  Long-term risk of recurrent cervical human papillomavirus infection and precancer and cancer following excisional treatment.

Authors:  Aimée R Kreimer; Mark Schiffman; Rolando Herrero; Allan Hildesheim; Paula González; Robert D Burk; Carolina Porras; Mark E Sherman; Franklin Demuth; Li Cheung; Concepción Bratti; Ana Cecilia Rodríguez
Journal:  Int J Cancer       Date:  2011-08-30       Impact factor: 7.396

Review 3.  Is default from colposcopy a problem, and if so what can we do? A systematic review of the literature.

Authors:  H Lester; S Wilson
Journal:  Br J Gen Pract       Date:  1999-03       Impact factor: 5.386

4.  Human papillomavirus (HPV) DNA triage of women with atypical squamous cells of undetermined significance with Amplicor HPV and Hybrid Capture 2 assays for detection of high-grade lesions of the uterine cervix.

Authors:  Simon Dufresne; Philippe Sauthier; Marie-Hélène Mayrand; Patrick Petignat; Diane Provencher; Pierre Drouin; Philippe Gauthier; Marie-Josée Dupuis; Bertrand Michon; Stéphan Ouellet; Rachid Hadjeres; Alex Ferenczy; Eduardo L Franco; François Coutlée
Journal:  J Clin Microbiol       Date:  2010-11-17       Impact factor: 5.948

5.  Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial.

Authors:  Cornelia L Trimble; Matthew P Morrow; Kimberly A Kraynyak; Xuefei Shen; Michael Dallas; Jian Yan; Lance Edwards; R Lamar Parker; Lynette Denny; Mary Giffear; Ami Shah Brown; Kathleen Marcozzi-Pierce; Divya Shah; Anna M Slager; Albert J Sylvester; Amir Khan; Kate E Broderick; Robert J Juba; Timothy A Herring; Jean Boyer; Jessica Lee; Niranjan Y Sardesai; David B Weiner; Mark L Bagarazzi
Journal:  Lancet       Date:  2015-09-17       Impact factor: 79.321

Review 6.  The impact of human papillomavirus vaccination on cervical cancer prevention efforts.

Authors:  L Stewart Massad; Mark Einstein; Evan Myers; Cosette M Wheeler; Nicolas Wentzensen; Diane Solomon
Journal:  Gynecol Oncol       Date:  2009-05-01       Impact factor: 5.482

7.  'See-and-treat' works for cervical cancer prevention: what about controlling the high burden in India?

Authors:  R Sankaranarayanan
Journal:  Indian J Med Res       Date:  2012-05       Impact factor: 2.375

8.  Single visit approach for management of cervical intraepithelial neoplasia by visual inspection & loop electrosurgical excision procedure.

Authors:  Shilpa Singla; Sandeep Mathur; Alka Kriplani; Nutan Agarwal; Pradeep Garg; Neerja Bhatla
Journal:  Indian J Med Res       Date:  2012-05       Impact factor: 2.375

9.  An electrical scalpel conization versus Shimodaira-Taniguchi conization procedure for cervical intraepithelial neoplasia.

Authors:  Keiko Kigure; Kazuto Nakamura; Yoshikazu Kitahara; Kohshiro Nakao; Takashi Hirakawa; Shunichi Rokukawa; Masahiro Ito; Toshio Nishimura; Ikuro Ito; Issei Kagami; Shunichi Itoga
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.